Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
attrition, ay, bid, blockade, contradictory, corroborated, Embedded, ERC, exit, fashion, fifteen, hand, hereunder, hierarchy, IL, illiquid, implicit, inflow, Inline, maker, marked, negate, orderly, outflow, overdue, piece, plasma, room, sophisticated, stability, Taxpayer, temperature, unexercised, unobservable, wage
Removed:
amounted, AP, applied, ASC, averse, Bayer, borrowing, calculate, Codification, community, consortium, disclose, disrupt, duration, Eaglet, element, EPS, explore, extinguishment, fact, formed, imputed, IP, Jersey, joint, lender, lent, minimal, modification, noting, Patheon, penny, PIPE, polysorb, premium, reluctant, replacing, Roth, seasoned, seize, SPA, steady, steering, Subordination, surfactant, tangible, terminating, unamortized, unconsolidated, Vivo
Financial report summary
?Competition
Pfizer • Nektar Therapeutics • Elite Pharmaceuticals • Cassava Sciences • Talphera • Zevra Therapeutics • PerrigoManagement Discussion
- In connection with our license agreement with Assertio for Oxaydo, we earn a royalty based on their net product sales, as defined in the license agreement. We recognized $130 thousand and $102 thousand of royalty revenue for Oxaydo during the years ended 2021 and 2020, respectively. We expect future lower royalties from lower net product sales of Oxaydo as Assertio has indicated Oxaydo is a non-promoted product.
- In connection with our license agreement with MainPointe for our Nexafed product line, we earn a royalty based on product net sales. We recognized $2 thousand and $7 thousand of royalty revenue on Nexafed during 2021 and 2020, respectively.
- We recognize license fees under the AD Pharma Amended Agreement for LTX-03. The monthly license payments ended on July 31, 2021 under the AD Pharma Amended Agreement. We recognized $1.4 million and $3.0 million of license fees revenue during the years ended 2021 and 2020, respectively.